Tag: PQ Bypass
Vascular News’ top 10 most popular stories of April 2021
Highlights from the Charing Cross (CX) 2021 Digital Edition (19–22 April, online)—including the potential of Philips’ Fiber Optic RealShape (FORS) technology to reduce radiation...
Endologix announces acquisition of PQ Bypass
Endologix recently announced it has completed the acquisition of PQ Bypass, a medical technology company pioneering a first-of-its-kind technology that addresses an unmet need...
DETOUR I two-year outcomes: “Excellent” functional improvement in complex PAD cohort
During a late-breaking data session at this year’s Vascular Interventional Advances annual meeting (VIVA 2020; 6–8 November, virtual), Ehrin Armstrong (University of Colorado, Denver,...
PQ Bypass completes enrolment in DETOUR II pivotal study
PQ Bypass has announced enrolment of the final subject in the company’s DETOUR II investigational device exemption (IDE) clinical trial. This milestone occurs only...
PQ Bypass receives FDA breakthrough device designation for its Detour system
PQ Bypass has announced that they received breakthrough device designation from the US Food and Drug Administration (FDA) for the Detour system. The Detour...
TORUS SFA stent graft pivotal study granted unconditional IDE approval
PQ Bypass recently announced it has received full approval of its investigational device exemption (IDE) trial of the company’s TORUS stent graft, a novel...
PQ Bypass announces US$60 million in financing for PAD treatment
Medical device company PQ Bypass has entered into an agreement that provides for up to an aggregate of US$60 million in equity financing, led...
DETOUR I 12-month data show promising durability of bypass system
Results from the DETOUR I trial evaluating the DETOUR System (PQ Bypass) for percutaneous bypass showed promising 12-month durability for patients with extremely long...
First patient treated in DETOUR II IDE trial
PQ Bypass has announced the enrolment of the first patients in the pivotal DETOUR II trial in the USA. The trial is a prospective,...
PQ Bypass receives IDE approval to initiate pivotal DETOUR II clinical...
PQ Bypass has received conditional approval of its investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate the pivotal...
PQ Bypass reports positive results for Detour system in patients with...
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour system for treating long-segment (>25cm)...
PQ Bypass announces CE mark for Detour percutaneous bypass technologies
PQ Bypass has announced CE mark approval for a trio of proprietary devices: the Torus stent graft system, PQ Snare, and PQ Crossing Device,...
Percutaneous bypass using femoral vein could be “an important step” in...
In a first-time data release, Dierk Scheinert presented six-month outcomes from the DETOUR trial of percutaneous bypass in long segment femoropopliteal occlusions at the...
Positive safety and efficacy results from PQ Bypass DETOUR I study...
PQ Bypass has announced that the DETOUR I trial has met its primary safety and efficacy endpoints.
The data were presented by Dierk Scheinert,...
